|
2026
|
Invention
|
Bioerodible ocular drug delivery insert and therapeutic method.
This invention relates to implan... |
|
2024
|
Invention
|
Tie-2 activators targeting the schlemm's canal.
Disclosed herein are compounds effective for act... |
|
2023
|
Invention
|
Method of treating an ocular condition by administering multispecific antibodies that activates t... |
|
|
Invention
|
Methods of treating intraocular pressure with activators of tie-2. Disclosed herein are compounds... |
|
|
Invention
|
Small molecule activators of tie-2. Disclosed herein are compounds effective for activation of Ti... |
|
2022
|
Invention
|
Method of treating an ocular condition by administering a humanized monoclonal antibodies that ta... |
|
|
Invention
|
Compositions, formulations and methods for treating ocular diseases. Disclosed herein are compoun... |
|
|
Invention
|
Tie-2 activators targeting the schlemm's canal. Disclosed herein are compounds effective for acti... |
|
2021
|
Invention
|
Methods for manufacture of small molecule activators of tie-2.
Disclosed herein are compounds ef... |
|
|
Invention
|
Methods for manufacture of small molecule activators of tie-2. Disclosed herein are compounds eff... |
|
|
Invention
|
Methods of treating acute respiratory distress syndrome with activators of tie-2. Disclosed herei... |
|
2020
|
Invention
|
Method of treating ocular conditions by administering an antibody that activates tie2 and binds v... |
|
|
Invention
|
Methods for treating vascular leak syndrome and cancer. Disclosed are methods for treating Vascul... |
|
|
Invention
|
Humanized monoclonal antibodies that target ve-ptp (hptp-beta). The disclosure provides compositi... |
|
|
Invention
|
Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof. Antibod... |
|
|
Invention
|
Humanized monoclonal antibodies that target ve-ptp (hptp-β). The disclosure provides compositions... |
|
2019
|
Invention
|
Multispecific antibodies that target hptp-β (ve-ptp) and vegf. The disclosure provides compositio... |
|
2018
|
Invention
|
Humanized monoclonal antibodies that target protein tyrosine phosphatase-beta (hptp-β/ve-ptp). Th... |
|
|
Invention
|
Methods of treating ocular conditions by administering humanized monoclonal antibodies that targe... |
|
|
Invention
|
Hptp-beta inhibitors. Disclosed herein are compounds effective for activation of Tie-2 and inhibi... |
|
2017
|
Invention
|
Humanized monoclonal antibodies that target ve-ptp (hptp-.beta.). The disclosure provides composi... |
|
|
Invention
|
Antibodies that target human protein tyrosine phosphatase-beta (hptp-beta) and methods of use the... |
|
|
Invention
|
Treatment of ocular disease. Disclosed are methods for treating eye diseases or conditions charac... |
|
2016
|
Invention
|
Compositions and methods for treating ocular diseases. Disclosed herein are compositions and meth... |
|
|
Invention
|
Methods of treating intraocular pressure with activators of tie-2. Disclosed herein are com... |
|
2015
|
Invention
|
Compounds, compositions, and methods for preventing metastasis of cancer cells. Disclosed are met... |
|
|
Invention
|
Combination of immunotherapies with activators of tie-2. The present invention relates to combina... |
|
|
Invention
|
Hptp-β inhibitors. Disclosed herein are compounds effective for activation of Tie-2 and inhibitio... |
|
2011
|
Invention
|
Compositions and methods for treating ocular edema, neovascularization and related diseases. Disc... |
|
|
Invention
|
Method for treating coronary artery disease using antibody binding human protein tyrosine phospha... |
|
2007
|
Invention
|
Antibodies that bind human protein tyrosine phosphatase beta (hptpβ). Antibodies and antigen bind... |
